AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02068170 — intervention group
Intervention type: DRUG
Intervention: Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib
Study NCT00386425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Description: intravenous
Study NCT01270386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib 750 mg p.o. once daily
Study NCT01270386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo p.o. once daily
Study NCT00112021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Study NCT02554318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Study NCT02554318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Study NCT02554318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Study NCT02554318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Study NCT02554318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Study NCT02554318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Study NCT02554318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Study NCT02554318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Study NCT02554318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented soybean
Study NCT01099774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% Formulation B Ophthalmic Solution
Description: One drop administered in each eye, every evening, for 12 weeks
Study NCT01099774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost 0.03% Ophthalmic Solution
Description: One drop administered in each eye, every evening, for 12 weeks
Study NCT00854919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atypical antipsychotic drug
Description: For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
Study NCT00854919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atypical antipsychotic drug
Description: For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
Study NCT00854919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure response prevention
Description: After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
Study NCT00854919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exposure response prevention
Description: After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
Study NCT00033657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29~Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles
Study NCT00033657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29~Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles
Study NCT00033657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29~Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles
Study NCT00033657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.
Study NCT00033657 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.
Study NCT02315872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: ACTH injections twice weekly for 28 weeks.
Study NCT02315872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections twice weekly for 28 weeks.
Study NCT04003454 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HCV Screening
Description: The investigators will perform a prospective pragmatic randomized effectiveness trial that will allow the investigators to directly compare 2 HCV screening methods while minimizing threats to internal validity. Patients will be screened for HCV infection using 1 of 2 interventions using a balanced patient-level random allocation scheme built into existing EHRs for each ED.
Study NCT03434249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium, BB-12® (Bifidolactis Infant)
Study NCT03434249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bifidolactis Infant Placebo
Study NCT04647656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen
Description: Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
Study NCT04647656 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
Study NCT02660606 — intervention group
Intervention type: OTHER
Intervention: Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)
Study NCT04713436 — intervention group
Intervention type: DRUG
Intervention: Differentiation Markers
Description: Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
Study NCT00672399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Subcutaneously injected, 10 mcg, single doses
Study NCT00672399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: oral, 400 mg tablet, single doses
Study NCT00672399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
Study NCT02340611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
Study NCT02340611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
Study NCT02258542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously
Study NCT00526331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigileo Monitor
Description: Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.
Study NCT00526331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloTrac Sensor
Description: Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.
Study NCT04407429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Analyses
Description: Storage of serum for SARS-CoV-2-antibodies and biomarkers
Study NCT02432859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: Direct current with sensory intensity for one hour
Study NCT02432859 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Direct current with zero intensity for one hour
Study NCT01916161 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Study NCT03816644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-Cog
Description: The 5-Cog is a 5 minute cognitive screen which will identify patients with 'cognitive impairment' from those with 'no cognitive impairment'.
Study NCT03816644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Literacy & Grip Assessment
Description: The health literacy and grip assessment will take approximately 5 minutes, and will test the patient's comprehension and pronunciation of health-related terms as well as strength in their dominant hand. The screen will sort out patients with 'low health literacy' and 'frail (low grip strength)' from those with normal health literacy and normal grip strength.
Study NCT01897610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immuncell-LC
Description: intravenous dripping of 200ml(10\^9\~2x10\^10 lymphocytes/60kg adult) for 1 hour
Study NCT01878734 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Powders
Description: Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.
Study NCT03774225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality with Manual and Verbal Guidance
Description: Participants will perform 4 balance games during 8 sessions with a manually and verbally assisted by a experient physiotherapist.
Study NCT03774225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality with Manual and Verbal Guidance
Description: Participants will perform 4 balance games during 8 sessions with a manually and verbally assisted by a experient physiotherapist.
Study NCT03774225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality with No Manual and Verbal Guidance
Description: Participants will perform 4 balance games during 8 sessions in the presence of a experient physiotherapist that will ensure patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game.
Study NCT03973047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bremelanotide
Description: Sterile aqueous solution for injection, provided as an autoinjector pen
Study NCT03973047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bremelanotide
Description: Sterile aqueous solution for injection, provided as an autoinjector pen
Study NCT03973047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: 8 mg tablet (over-encapsulation in a capsule)
Study NCT03973047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule
Study NCT03774225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality with No Manual and Verbal Guidance
Description: Participants will perform 4 balance games during 8 sessions in the presence of a experient physiotherapist that will ensure patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game.
Study NCT03774225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients of the control group will be trained with balance exercises by a experient physiotherapist.
Study NCT03774225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients of the control group will be trained with balance exercises by a experient physiotherapist.
Study NCT03259672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane was used as a maintenance anesthetic agent.
Study NCT03259672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane was used as a maintenance anesthetic agent.
Study NCT02262598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT02262598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorthiazide (HCTZ)
Study NCT02262598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/HCTZ fixed dose
Study NCT03907930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous nephrolithotripsy
Description: removal of kidney and upper ureteric stones through small incision in the loin using nephroscope after disintegration by lithoclast
Study NCT03412188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy will receive a total daily dose of eltrombopag of (25-50mg/d)
Study NCT03412188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: Patients who are currently receiving conventional lines of treatment (steroids, IVIG, azathioprine, and rituximab, Mycophenolate mofetil) will continue on the same line of treatment
Study NCT03188809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Adductor channel is roughly triangular in cross section and is bounded by three muscles: quadriceps anterolaterally (specifically vastusmedialis), sartorius medially and adductor magnus posteriorly. Within this canal is the femoral artery, femoral vein, the posterior branch of the obturator nerve, and branches of the femoral nerve; specifically the saphenous nerve and nerve to vastus medialis. When the femoral artery is shown by ultrasonography 21 gauge, 50 mm needle in-plane technique and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
Study NCT03188809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral nerve block
Description: The probe is placed just below the inguinal crease , when the femoral artery is shown by ultrasonography, the femoral nerve stays in the lateral direction and 21 gauge, 50 mm needle will be advanced from the anterior to the posteriomedial with an in-plane technique and the catheter will be inserted by the peripheral nerve stimulator in the lateral femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
Study NCT04029792 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of plant extracts (BSL_EP028)
Description: Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
Study NCT04491305 — intervention group
Intervention type: PROCEDURE
Intervention: Surgically treated women with endometriosis and confirmed diagnosis
Description: Women with indication for surgery or diagnostic laparoscopy will be enrolled in study.
Study NCT00756600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
Study NCT03969082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Description: Students will read to patients during 30 minutes. They will read aloud and pause regularly to encourage patients to reflect on what is being read, on the thoughts the poem or book has stirred or on how the reading matter relates to their own lives.
Study NCT00756600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
Study NCT02322502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: inhalation with laryngeal mask to maintain anaesthesia
Study NCT02322502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: inhalation with laryngeal mask to maintain anaesthesia
Study NCT02322502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: intravenous injection to maintain anaesthesia
Study NCT01959698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01959698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT01959698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01959698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT01959698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01959698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01959698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02382796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
Study NCT00637806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate concentrated suspension 110 mg/mL
Description: Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
Study NCT00637806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate concentrated suspension 60 mg/mL
Description: Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
Study NCT00637806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension, 5 mL once daily
Study NCT04561297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TDC differential value
Description: TDC measurements in all patients agreeing to participate who are scheduled for a biopsy of a breast tumor or mass
Study NCT02888353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: MRI
Description: Perform MRI in patients with cardiac devices
Study NCT01541670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Description: Intravenous injection
Study NCT04029792 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
Study NCT06729905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yerba mate tea
Description: Consumption of three cups per day of a beverage prepared with yerba mate
Study NCT06729905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control drink
Description: Consumption of water or an isotonic drink, free of polyphenols or caffeine. Abstention of consuming coffee.
Study NCT01087580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Prednisone
Description: A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
Study NCT01087580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index \< 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week.
Study NCT05085106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac trometamol eye drop
Description: Felbinac trometamol eye drop: 0.025%、0.05%、0.1%、0.2%、0.3%, 1 drop will be instilled as instructed over one day in single-dose study; 0.1%, 0.2%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.